IP Library Granted Patent US 12,683,029
Granted Patent B2
US 12,683,029 · App. 17/710,326 · Granted Jul 14, 2026

System and method for detecting recurrence of a disease

Inventors: Sanghee Cho (Niskayuna, NY); Zhanpan Zhang (Niskayuna, NY); Soumya Ghose (Niskayuna, NY); Fiona Ginty (Saratoga Springs, NY); Cynthia Elizabeth Landberg Davis (Niskayuna, NY); Jhimli Mitra (Niskayuna, NY); Sunil S. Badve (Indianapolis, IN); Yesim Gokmen-Polar (Noblesville, IN)
Assignees: GE PRECISION HEALTHCARE LLC; THE TRUSTEES OF INDIANA UNIVERSITY
G16H50/30G06N3/045G06T7/0014G16H30/00G06T2207/30068
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,683,029
App. No.
17/710,326
Filed
Mar 31, 2022
Granted
Jul 14, 2026
Kind
B2
Art Unit
2661
USPC
382/100
Abstract

A method for determining a recurrence of a disease in a patient is presented. The method includes generating a plurality of medical images of an organ of the patient and determining a plurality of recurrence probabilities from the plurality of medical images. A recurrence of the disease is determined based on the plurality of recurrence probabilities and clinicopathological data of the patient using a Bayesian network.

Claims (26)

1 . A method for determining a recurrence of a disease in a patient, the method comprising:

generating a plurality of medical images of an organ of the patient from at least a first modality and a second modality, and wherein the plurality of medical images comprises X-ray images, Hematoxylin and Eosin (H&E) biopsy sample images, molecular images, Positron emission tomography (PET) scans images, ultrasound images, Magnetic resonance imaging (MRI) scan images or combinations thereof;

determining a plurality of recurrence probabilities from the plurality of medical images; and

determining a recurrence of the disease based on the plurality of recurrence probabilities and clinicopathological data of the patient using a Bayesian network,

wherein the plurality of recurrence probabilities includes a first recurrence probability determined by a pathomics learning model and a second recurrence probability determined by a radiomics learning model, and

wherein determining the first recurrence probability comprises extracting fixed image patches of predefined pixels from H&E biopsy sample images and automatically mapping each of the fixed image patches to an initial latent space, and providing the initial latent space to a dense network that classifies the initial latent space into aggressive patches and non-aggressive patches, and wherein the first recurrence probability is based on the aggressive and non-aggressive patches, and

wherein determining the second recurrence probability comprises extracting and analyzing a plurality of radiomics features from an invasive edge surrounding the disease observed in routine mammogram images.

2 . The method of claim 1 , wherein the plurality of recurrence probabilities includes a third recurrence probability.

3 . The method of claim 2 , wherein the third recurrence probability is determined based on in situ imaging on a small set of tissue images of the patient.

4 . The method of claim 1 , wherein determining the first recurrence probability further comprises refining the latent space by encoding patches generated by a generative adversarial network (GAN) model that captures features of aggressive cancers.

5 . The method of claim 4 , wherein determining the first recurrence probability further comprises using a deep learning (DL) network to predict the first recurrence probability based on the refined latent space.

6 . The method of claim 1 , wherein the clinicopathological data of the patient includes age, size, location, laterality and Lymph node positivity of the disease.

7 . The method of claim 6 , wherein the plurality of recurrence probabilities and clinicopathological data values represent a plurality of nodes in the Bayesian network and the Bayesian network determines the disease recurrence, depending on the node probability values and conditional probabilities between the nodes.

8 . A system comprising:

a memory;

a display device; and

a processor communicably coupled to the memory and configured to:

generate a plurality of medical images of an organ of the patient from at least a first modality and a second modality, and wherein the plurality of medical images comprises X-ray images, Hematoxylin and Eosin (H&E) biopsy sample images, molecular images, Positron emission tomography (PET) scans images, ultrasound images, Magnetic resonance imaging (MRI) scan images or combinations thereof;

determine a plurality of recurrence probabilities from the plurality of medical images; and

determine a recurrence of the disease based on the plurality of recurrence probabilities and clinicopathological data of the patient using a Bayesian network,

wherein the plurality of recurrence probabilities includes a first recurrence probability determined by a pathomics learning model and a second recurrence probability determined by a radiomics learning model, and

wherein determining the first recurrence probability comprises extracting fixed image patches of predefined pixels from H&E biopsy sample images and automatically mapping each of the fixed image patches to an initial latent space, and providing the initial latent space to a dense network that classifies the initial latent space into aggressive patches and non-aggressive patches, and wherein the first recurrence probability is based on the aggressive and non-aggressive patches, and

wherein determining the second recurrence probability comprises extracting and analyzing a plurality of radiomics features from an invasive edge surrounding the disease observed in routine mammogram images.

9 . The system of claim 8 , wherein the pathomics model further includes a generative adversarial network (GAN) model that generates synthetic image samples to further refine the latent space.

10 . The system of claim 9 , wherein the pathomics model comprises a deep learning (DL) network to predict the first recurrence probability based on the refined latent space.

11 . The system of claim 8 , wherein the plurality of recurrence probabilities and clinicopathological data values represent a plurality of nodes in the Bayesian network and the Bayesian network determines the disease recurrence, depending on the node probability values and conditional probabilities between the nodes.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2022
From: CHO, SANGHEE; ZHANG, ZHANPAN; GHOSE, SOUMYA; GINTY, FIONA; DAVIS, CYNTHIA ELIZABETH LANDBERG; MITRA, JHIMLI
To: GE PRECISION HEALTHCARE LLC
Reel/Frame 059463/0234 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2022
From: BADVE, SUNIL S.; GOKMEN-POLAR, YESIM
To: THE TRUSTEES OF INDIANA UNIVERSITY
Reel/Frame 059463/0581 →
Continuity (1)
Related Publication 20230317293A1 · Oct 5, 2023
References Cited (48)
US 9398893B2 · Stavros · 2016 [cited by examiner]
US 10380739B2 · Vega · 2019 [cited by examiner]
US 10540570B2 · Madabhushi · 2020 [cited by examiner]
US 11574404B2 · Madabhushi · 2023 [cited by examiner]
US 11676703B2 · Vaidya · 2023 [cited by examiner]
US 12019674B2 · Wang · 2024 [cited by examiner]
US 12334190B2 · Ma · 2025 [cited by examiner]
US 20090239229A1 · Weaver · 2009 [cited by applicant]
US 20170193175A1 · Madabhushi · 2017 [cited by examiner]
US 20180276498A1 · Madabhushi · 2018 [cited by examiner]
US 20180336395A1 · Madabhushi · 2018 [cited by examiner]
US 20190087532A1 · Madabhushi · 2019 [cited by examiner]
US 20190087693A1 · Madabhushi · 2019 [cited by examiner]
US 20190254611A1 · Madabhushi · 2019 [cited by examiner]
US 20190259156A1 · Madabhushi · 2019 [cited by examiner]
US 20200278350A1 · Brady-Kalnay · 2020 [cited by examiner]
US 20200315589A1 · Stavros · 2020 [cited by examiner]
US 20210110541A1 · Vaidya · 2021 [cited by examiner]
US 20220058801A1 · Klimov · 2022 [cited by examiner]
US 20220328134A1 · Ma · 2022 [cited by examiner]
US 20230242992A1 · Lindley · 2023 [cited by examiner]
US 20230307137A1 · Ghose · 2023 [cited by examiner]
US 20230309836A1 · Ghose · 2023 [cited by examiner]
US 20230342933A1 · Lou · 2023 [cited by examiner]
US 20240347207A1 · Singhal · 2024 [cited by examiner]
US 20240404707A1 · Luo · 2024 [cited by examiner]
US 20250166828A1 · Hiremath · 2025 [cited by examiner]
EP 4224479A1 · 2023 [cited by examiner]
WO WO2008124138A1 · 2008 [cited by examiner]
WO 2009114862A1 · 2009 [cited by applicant]
WO WO2022029492A1 · 2022 [cited by examiner]
WO WO2022036869A1 · 2022 [cited by examiner]
WO WO2022157775A1 · 2022 [cited by examiner]
WO WO2022221712A1 · 2022 [cited by examiner]
WO WO2025110881A1 · 2025 [cited by examiner]
Braman et al., “Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 {ERBB2)-Positive Breast Cancer.” JAMA network open vol. 2,4 e192561. Apr. 5, 2019… [cited by examiner]
Braman et al., “Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.” Breast cancer research : BCR vol. 19, 1 57. … [cited by examiner]
Sali et al., “Deep Learning for Whole-Slide Tissue Histopathology Classification: A Comparative Study in the dentification of Dysplastic and Non-Dysplastic Barrett's Esophagus.” Journal of personalized medicine vol. 10,… [cited by examiner]
Sari et al., “Unsupervised Feature Extraction via Deep Learning for Histopathological Classification of Colon Tissue mages,” IEEE Trans Med Imaging. May 2019;38{5):1139-1149, 11 pages. (Year: 2019). [cited by examiner]
Sedghi et al. “Deep neural maps for unsupervised visualization of high-grade cancer in prostate biopsies.” International Journal of computer assisted radiology and surgery vol. 14,6 (2019): 1009-1016, 16 pages. (Year: 2… [cited by examiner]
Afshar et al.; “From Hand-Crafted to Deep Learning-based Cancer Radiomics: Challenges and Opportunities”; arXiv; arXiv: 1808.07954; pp. 1-31; <https://doi.org/10.48550/arXiv.1808.07954> (Year: 2019). [cited by examiner]
Braman et al., “Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)-Positive Breast Cancer.” JAMA network open vol. 2,4 e192561. Apr. 5, 2019… [cited by applicant]
Braman et al., “Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI.” Breast cancer research : BCR vol. 19,1 57. M… [cited by applicant]
Sali et al., “Deep Learning for Whole-Slide Tissue Histopathology Classification: A Comparative Study in the Identification of Dysplastic and Non-Dysplastic Barrett's Esophagus.” Journal of personalized medicine vol. 10… [cited by applicant]
Sari et al., “Unsupervised Feature Extraction via Deep Learning for Histopathological Classification of Colon Tissue Images,” IEEE Trans Med Imaging. May 2019;38(5):1139-1149, 11 pages. [cited by applicant]
Sedghi et al. “Deep neural maps for unsupervised visualization of high-grade cancer in prostate biopsies.” International journal of computer assisted radiology and surgery vol. 14,6 (2019): 1009-1016, 16 pages. [cited by applicant]
Bera Kaustav et al: “Artificial intelligence in digital pathology—new tools for diagnosis and precision oncology”, Nature Reviews Clinical Oncology, Nature, NY, US, vol. 16, No. 11, Aug. 9, 2019, pp. 703-715, XP36911541… [cited by applicant]
EP application 23161730.9 filed Mar. 14, 2023—extended Search Report issued Aug. 25, 2023; 11 pages. [cited by applicant]